牛铭山，博士、教授、博士生导师，美国俄亥俄州立大学访问学者，江苏省“333工程”中青年科学技术带头人、江苏省优秀青年基金获得者、江苏省“六大人才高峰”高层次人才、江苏省“青蓝工程”优秀青年骨干教师、校青年特聘教授。主要从事急性髓系白血病发病机制与靶向治疗、CAR-T细胞治疗血液肿瘤等方向的研究。近年，主持国家自然科学基金项目3项、江苏省重点研发计划（社会发展）项目1项、江苏省优秀青年基金1项、江苏省自然科学基金等省部级项目5项。申请/授权国家发明专利4项，获得江苏省医学新技术引进奖一等奖1项。以第一/通讯作者在Blood(IF:21.1), Journal of Hematology & Oncology(IF:29.9)，Blood Advances(IF:7.4)等杂志发表SCI收录论文30余篇。

 

欢迎有志于从事血液肿瘤研究的优秀同学报考研究生（学术型硕士、基础医学学术型博士、临床医学专业学位博士）；在职攻读临床医学（血液病学）专业学位博士需提前联系，确定有充足的时间脱产完成学习和科研任务。我们以徐州医科大学附属医院血液科和江苏省骨髓干细胞重点实验室为依托，为研究生提供优越的科研平台和科研条件，实验室具有良好的科研氛围。

 

1.   Sha Ma, Jieyun Xia, Miao Zhang, Wenyu Li, Meng Xiao, Yuqian Sha, Wenya Wang, Jianteng Zhou, Ying Wang, Kunming Qi, Chunling Fu, Zengtian Sun, Dian Zhou, Qian Sun, Tingting Qiu, Zhiling Yan, Feng Zhu, Wei Chen, Hai Cheng, Wei Sang, Jiang Cao, Depeng Li, Zhenyu Li, Mariateresa Fulciniti, Yao Yao*, Kailin Xu*, Mingshan Niu* (通讯作者). Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma, Blood, 2025, Online. (一区, IF: 21.1)

2.   Yao Yao, Mei Yuan, Min Shi, Wenyu Li, Yuqian Sha, Yan Zhang, Canli Yuan, Jianping Luo, Zhenyu Li, Chengcheng Liao, Kailin Xu*, Mingshan Niu* (通讯作者). Halting Multiple Myeloma with MALT1 Inhibition: Suppressing BCMA-Induced NF-κB and Inducing Immunogenic Cell Death, Blood Advances, 2024, 8(15): 4003-4016. (一区, IF: 7.4)

3.   Xuejiao Liu, Yulong Chong, Yiming Tu, Ning Liu, Chenglong Yue, Zhenglei Qi, Huize Liu, Yao Yao, Hongmei Liu, Shangfeng Gao, Mingshan Niu* (通讯作者), Rutong Yu *. CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways. Journal of Hematology & Oncology. 2016, 9(1):108. (一区, IF: 29.9)

4.   Meifeng Zeng, Shuang Sun, Hao Feng, Zhoupeng Tan, Jiangyan Zhao, Yiqing Wu, Weiqun Yuan, Zheng Li, Jingying Qiu, Mingshan Niu* (通讯作者), Xiaoke Gu*. Discovery of novel third generation P-glycoprotein inhibitors bearing an azo moiety with MDR-reversing effect. Eur J Med Chem, 2024, 280:116943. (一区, IF: 6.7)

5.   Chunyu Jiang, Ting Pan, Yunxiang Jiang, Zhiyu Zhang, Meifeng Zeng, Shuang Sun, Zheng Li, Yiqing Wu, Jingying Qiu, Mingshan Niu* (通讯作者), Xiaoke Gu*. Design and evaluation of dibenzoazepine-tetrahydroisoquinoline hybrids as potential P-glycoprotein inhibitors against multidrug resistant K562/A02 cells. Eur J Med Chem, 2023 Mar 5:249:115150. (一区, IF: 6.7)

6.   Xuejiao Liu, Xiangyu Chen, Lin Shi, Qianqian Shan, Qiyu Cao, Chenglong Yue, Huan Li, Shengsheng Li, Jie Wang, Shangfeng Gao, Mingshan Niu* (通讯作者), Rutong Yu *. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma. J Exp Clin Cancer Res. 2019, 38(1):219. (一区, IF: 11.4)

7.   Ting Pan, Sijia Wang, Hao Feng, Jiawen Xu, Miao Zhang, Yao Yao, Kailin Xu*, Mingshan Niu* (通讯作者). Preclinical evaluation of the ROCK1 inhibitor, GSK269962A, in acute myeloid leukemia. Front Pharmacol, 2022, 13:1064470. (SCI, IF: 5.6)

8.   Ninghan Zhang, Jiawen Xu, Rong Wang, Ting Pan, Huanxin Zhang, Lingling Yin, Yao Yao, Linyan Xu, Shengyun Zhu, Qingyun Wu, Zhenyu Li, Xuejiao Liu, Kailin Xu*, Mingshan Niu* (通讯作者). CARMA1 is required for Notch1-induced NF-κB activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia. J Mol Med, 2021, 99(10):1447-1458. (SCI, IF: 5.606)

9.   Rong Wang, Huihui Zhang, Jiawen Xu, Ninghan Zhang, Ting Pan, Xiaomin Zhong, Huanxin Zhang, Lingling Yin, Yao Yao, Qingyun Wu, Zhenyu Li, Xuejiao Liu, Kailin Xu*, Mingshan Niu* (通讯作者). MALT1 Inhibition as a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia by Blocking Notch1-Induced NF-κB Activation. Front Oncol, 2020, 10:558339. (SCI, IF: 5.738)

10. Bin Pan, Jun Gao, Wei Chen, Cong Liu, Longmei Shang, Mengdi Xu, Chunling Fu, Shengyun Zhu, Mingshan Niu* (通讯作者), Kailin Xu*. Selective inhibition of interleukin-1 receptor-associated kinase 1 ameliorates lipopolysaccharide-induced sepsis in mice. Int Immunopharmacol, 2020, 85:106597. (SCI, IF: 5.714)

11. Huihui Zhang, Ninghan Zhang, Rong Wang, Tingting Shao, Yuan Feng, Yao Yao, Qingyun Wu, Shengyun Zhu, Jiang Cao, Huanxin Zhang, Zhenyu Li, Xuejiao Liu, Mingshan Niu*(通讯作者), Kailin Xu*. High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia. J Transl Med. 2019, 17(1):106. (SCI, IF: 6.1)

12. Mingshan Niu, Ninghan Zhang, Rong Wang, Tingting Shao, Yuan Feng, Yangling Shen, Xuejiao Liu, Kai Zhao, Shengyun Zhu, Linyan Xu, Yao Yao*, Kailin Xu*. MiR-340 Is a Biomarker for Selecting Treatment Between Chemotherapy and Allogeneic Transplantation in Acute Myeloid Leukemia. Front Oncol. 2019, 9:1058. (SCI, IF: 5.738)

13. Qi Jialei, Gao Xiang, Zhong Xiaomin, Zhang Ninghan, Wang Rong, Zhang Huihui, Pan Ting, Liu Xuejiao, Yao Yao, Wu Qingyun, Mingshan Niu*(通讯作者), Kailin Xu*. Selective inhibition of Aurora A and B kinases effectively induces cell cycle arrest in t(8,21) acute myeloid leukemia. Biomed Pharmacother. 2019, 117:109113. (SCI, IF: 6.529)

14. Mingshan Niu, Yuan Feng, Ninghan Zhang, Tingting Shao, Huihui Zhang, Rong Wang, Yao Yao, Ruosi Yao, Qingyun Wu, Jiang Cao, Xuejiao Liu, Yubo Liu*, Kailin Xu*. High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia. Cancer Cell Int. 2019, 19:122. (SCI, IF: 5.722)

15. Chen Yang, Tingting Shao, Huihui Zhang, Ninghan Zhang, Xiaoying Shi, Xuejiao Liu, Yao Yao, Linyan Xu, Shengyun Zhu, Jiang Cao, Hai Cheng, Zhiling Yan, Zhenyu Li, Mingshan Niu*(通讯作者), Kailin Xu*. MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy. J Transl Med. 2018, 16(1):267. (SCI, IF: 6.1)

16. Mingshan Niu, Yangling Shen, Jialei Qi, Xuejiao Liu, Wei Sang, Qingyun Wu, Jiang Cao, Wei Chen, Yao Yao*, Kailin Xu*. Effects of realgar (As4S4) on degradation of PML-RARA harboring acquired arsenic-resistance mutations. Ann Hematol. 2017, 96(11):1945-1948. (SCI, IF:3)

 

1.    国家自然科学基金，靶向诱导Myb转录因子相转化治疗急性髓系白血病的机制研究，2023/01-2026/12，52万元。

2.    国家自然科学基金，新型PML-RARA抑制剂通过自噬途径诱导APL细胞分化与凋亡的作用机制，2017/01-2020/12，57万元。

3.    国家自然科学基金，SUMO化调控CARMA1信号在ABC型弥漫大B细胞淋巴瘤发病中的作用及机制，2015/01-2017/12，23万元。

4.    江苏省重点研发计划，新型靶向药物治疗急性早幼粒细胞白血病的转化研究，2017/07-2020/06，200万元。

5.    江苏省优秀青年基金，蛋白水平修饰CARMA1调控弥漫大B细胞淋巴瘤增殖的作用机制，2018/07-2021/06，50万元。

6.      江苏省高校重大项目，靶向髓系转录因子治疗急性髓系白血病的作用与机制，2021/10-2024/09，30万元。